Recognition of this molecular subset is vital, as <i>NFE2L2</i> mutations are theoretically linked to resistance to standard platinum-based regimens, potentially necessitating therapeutic strategies distinct from standard SCLC algorithms. The gene discussed is NFE2L2; the disease is small cell lung carcinoma.